Dostarlimab, used in combination with other treatments, has shown durable disease control in patients with dMMR/MSI-H endometrial cancer. The treatment may have curative potential in advanced cases of this cancer type, though considerations of benefit and risk are also being discussed. Research on dostarlimab and its role in treating endometrial cancer is ongoing, with some studies suggesting significant long-term benefits.